$126,000 to Seven Recipients: Canadian Radiation Oncology Foundation
sanofi-aventis Research Innovation Awards (CASARIA Awards)
OTTAWA, June 29, 2011 /CNW Telbec/ - Seven Canadian radiation
oncologists will conduct novel research into new anticancer medicines
and targeted radiation therapy focused on gastrointestinal or prostate
cancer with support from sanofi-aventis Research Innovation Awards. A selection
committee of members of the Canadian Radiation Oncology Foundation
(CROF) chose the 2011 recipients from a field of 34 applicants.
Dr. Laura Dawson, CASARIA Advisory Council Chair, states, "The number
and high quality of the 34 proposals focusing on radiation research for
prostate, colorectal, liver and esophageal cancers are indicators of
the strong research ongoing across Canada related to radiation
Highlights of the 2011 research initiatives include:
Dr. Vikram Velker of London Regional Cancer Centre will conduct an international study to
highlight variations in treatment planning for men requiring
radiotherapy following surgery for prostate cancer, resulting in more
standardized and effective treatment to maximize cure rates and
minimize side effects.
Dr. Eric Vigneault of CHUQ Hôtel-Dieu de Québec will study and recommend the ultimate focal
image-guided therapy to eradicate prostate cancer inside the gland,
based on findings from FECh TEP/CT scans.
Dr. Michael Lock of London Regional Cancer Program will assess a new test that may be
able to detect cancer cells that have escaped into the bloodstream of
patients with liver cancer, enabling predictions about which patients
would benefit from treatment that goes through the bloodstream, and
identify those patients who can avoid toxic treatments.
Dr. Anne Koch of Princess Margaret Hospital will examine whether radiation combined
with a PARP inhibitor, an anti-cancer agent which makes cancer cells
more sensitive to radiation therapy, may be a more effective approach
to treating liver cancer.
Dr. Barbara Fisher of London Regional Cancer Program will conduct a study involving the use
of preoperative imaging with 3T MRI and PET-CT scans to study tumour
perfusion, lymph node status and downstaging of rectal cancers by
Dr. Neil D'Souza, Radiation Therapist, of Odette Cancer Centre will develop a unique 'nomogram' (a predictive
tool that can be used to help estimate the risk of cancer being
progression-free after treatment, based on certain factors) for
high-risk prostate cancer patients who require radiation treatment and
long-term hormone therapy.
Dr. Robert Bristow of Princess Margaret Hospital will study prostate cancer cells and try
to develop a new test that will search out the cells for rare cancer
stem cells. These cells can be the basis of resistance to radiotherapy
and chemotherapy, and a search and destroy approach may improve the
chances for cure.
"The Canadian Radiation Oncology Foundation is very pleased to be able
to facilitate the award of these important grants, made possible by the
generous support of sanofi-aventis," states Dr. John Hay, a member of
the CROF Board. Full details of the $126,000 in financial awards are
available in a separate chart, posted on the CROF web site: http://www.caro-acro.ca/Links/CROF.htm
"From detecting the early stages of gastrointestinal and prostate
cancers, to evaluating the effectiveness of new treatments, this
research will have a tangible impact on the lives of cancer patients
and their families," says Hugh O'Neill, President and CEO of
sanofi-aventis. "At sanofi-aventis we care about health and supporting
projects such as this. It is how we can make a difference, both now and
in the years to come. We are proud to be part of this initiative."
About the Canadian Radiation Oncology Foundation (CROF)
The Canadian Radiation Oncology Foundation is a not-for-profit
charitable organization, working with the public and the oncology
community through a broad educational program to enhance public
awareness of the crucial role radiation oncology in national cancer
care. Through its support for professional education and scientific
research in radiation medicine, CROF aims to provide Canadians with the
highest standard of radiation treatment, with the ultimate goal of
reducing the burden and suffering of all Canadians diagnosed with
cancer. CROF web site: http://www.caro-acro.ca/Links/CROF.htm
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer healthcare, emerging markets and animal health.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is represented in Canada by the pharmaceutical company
sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines
company Sanofi Pasteur Limited, based in Toronto, Ontario. Together
they employ more than 2,000 people across the country. With combined
R&D investments of $159.2 million in 2010, they are leaders in Canada's
biopharmaceutical sector, a critical knowledge-based industry that
generates jobs, business and opportunity throughout the country.
SOURCE CANADIAN RADIATION ONCOLOGY FOUNDATION (CROF)
For further information:
Judy McLarty, APR, 1.604.740.5839 or email@example.com